Generic Name and Formulations:
Dutasteride 0.5mg, tamsulosin HCl 0.4mg; caps.
Indications for JALYN:
Benign prostatic hyperplasia (BPH). Limitations of use: not approved for preventing prostate cancer.
Swallow whole. Take 1 cap daily approx. 30mins after the same meal each day.
Not for use in children. Pregnant women and those of childbearing potential should avoid handling caps. Pregnancy (Cat.X). Nursing mothers.
Increased risk of high-grade prostate cancer. Monitor prostate specific antigen (PSA) values (set new baseline PSA after 3–6 months of treatment); double PSA levels to compare with normal values. Rule out prostate cancer and other urological disorders prior to treatment. Syncope. End-stage renal disease. Severe hepatic impairment. Cataract and glaucoma surgery (intraoperative floppy iris syndrome possible); do not initiate tamsulosin-containing products. Poor metabolizers (low CYP2D6 activity). Sulfa allergy. Avoid donating blood until at least 6 months after last dose.
Concomitant strong CYP3A4 inhibitors (eg, ketoconazole): not recommended. Caution with moderate CYP3A4 inhibitors (eg, erythromycin), strong (eg, paroxetine) or moderate (eg, terbinafine) CYP2D6 inhibitors, or a combination of both CYP3A4 and CYP2D6 inhibitors. Do not use with other alpha-blockers. Potentiated by cimetidine. Dutasteride may be potentiated by CYP3A4/5 inhibitors (eg, ritonavir, diltiazem, verapamil, erythromycin). Caution with PDE-5 inhibitors (may increase orthostatic hypotension). Monitor warfarin.
Type I and II 5 alpha-reductase inhibitor + alpha-1A blocker.
Ejaculation disorders, impotence, decreased libido, dizziness, breast disorders, orthostatic hypotension and/or syncope; rare: priapism.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma